Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease

The control of plasma lipids, and especially LDL-C levels is one of the actions on which clinical guidelines for reducing the risk of suffering a cardiovascular event are based, especially in secondary prevention. Cardiovascular prevention starts with lifestyles: a healthy diet, weight control and physical exercise. Statins are the first line drug due to the large body of evidence demonstrating their safety and efficacy. With the advent of drugs that allow major reductions in LDL-C levels, clinical practice guidelines have gradually reduced their limits for this substance, especially in patients with established cardiovascular disease.

Authors

Institutions

Publication Details

Journal
Boletín de información farmacoterapéutica de Navarra
Published
2025-01-01
DOI
https://doi.org/10.54095/bitn20253202en
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease

Javier Garjón
1 links
Boletín de información farmacoterapéutica de Navarra
Lipoproteins and Cardiovascular Health
article

Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease

Javier Garjón
article en

Abstract

The control of plasma lipids, and especially LDL-C levels is one of the actions on which clinical guidelines for reducing the risk of suffering a cardiovascular event are based, especially in secondary prevention. Cardiovascular prevention starts with lifestyles: a healthy diet, weight control and physical exercise. Statins are the first line drug due to the large body of evidence demonstrating their safety and efficacy. With the advent of drugs that allow major reductions in LDL-C levels, clinical practice guidelines have gradually reduced their limits for this substance, especially in patients with established cardiovascular disease.

Boletín de información farmacoterapéutica de Navarra
Navarre Institute of Health Research (ES)
Openalex Percentile: Top 70%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.